Asia
Suzhou Zelgen Biosciences completed a $62M series B financing to support its portfolio of small molecule and biologic drug candidates.
Here’s a look at the top six generic drug companies to work for.
The fine was over Teva paying bribes to foreign officials to win business in Russia, Ukraine and Mexico, the ministry said.
Hua Medicine of Shanghai expects to spend $200M over the next three years on its novel oral diabetes 2 treatment, dorzagliatin.
The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion.
Suzhou Kintor Pharma raised $44M in a funding led by Shenzhen Green Pine Capital Partners.
The medtech titan was told to make a public apology and remove the content.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
According to a SEC filing, the cost of the facility will be paid in part by the State of New York.
Shanghai Fosun Pharma announced a $50M U.S. joint venture, a JV that includes two Fosun entities.
PRESS RELEASES